Today news
About the same in other media
Post-lockdown colds spur sales at Strepsils and Nurofen maker
Reading now: 574
Reckitt Benckiser enjoyed better than expected results thanks to demand for its treatments for coughs, colds and flu, following a rise in cases after the lifting of global lockdowns.
The Berkshire-based consumer goods company recorded a “sharp improvement” in demand for its Strepsils, Mucinex and Nurofen after social mixing returned, with sales of over-the-counter medicines rising more than 20% in the three months to September.
That drove like-for-like sales up 3.3% in the quarter, compared with the 0.7% drop analysts had expected. As a result, Reckitt said like-for-like revenue for the full year would be up 1 to 3%, up from earlier estimates of 0 to 2%.
Growth will still be lower than last year, when demand for cleaning products during the
Read more on theguardian.comAbout this in other media
Elon Musk targets Bernie Sanders over tax: ‘I keep forgetting you’re still alive’ theguardian.com /2 years ago
‘An emblem of Scotland’: how Irn-Bru stole the show at Cop26 theguardian.com /2 years ago
COVID-19: Dutch 'partial lockdown' expected, Austria and Germany mull new restrictions euronews.com /2 years ago
Show more
The website finance-news.co. is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.
